Healthcare Industry News: Allograft
News Release - November 9, 2006
Regeneration Technologies Announces Launch of Pre-Shaped Achilles Tendon Sterilized Through the BioCleanse(R) ProcessALACHUA, Fla., Nov. 9 (HSMN NewsFeed) -- Regeneration Technologies, Inc. (RTI) (Nasdaq: RTIX ), the Florida-based processor of orthopedic, cardiovascular and other biologic implants, announces the launch of the pre- shaped Achilles tendon sterilized through the BioCleanse® process at the fall meeting of the Arthroscopy Association of North America (AANA). The pre-shaped Achilles can be used in anterior cruciate ligament (ACL) repair, posterior cruciate ligament (PCL) repair and shoulder reconstruction.
With the launch of the pre-shaped Achilles, RTI now provides surgeons a total sterile solution for tendon and bone graft needs. Other sterilized sports medicine implants currently available include the Adjustable Length Bone-Tendon-Bone (BTB), pre-shaped BTB, tibialis tendons, semitendinosus tendons, gracilis tendons, Sterling® Wedge and Sterling® Interference Screws.
RTI's automated and validated BioCleanse system is a low-temperature chemical sterilization process that eliminates the risk of donor to recipient disease transmission while retaining the tissue's biomechanical integrity.
"We invented BioCleanse with the idea that through science we can provide surgeons and their patients with sterilized implants they know are safe," said Brian K. Hutchison, RTI chairman, president and chief executive officer. "We take our responsibilities to patients and surgeons seriously and are committed to raising the bar in science, safety and innovation."
The pre-shaped Achilles will be available through RTI's direct representatives and distributors. Information will be available at AANA, booth 314, or by contacting an RTI representative at (800) 624-7238.
About Regeneration Technologies, Inc.
RTI processes Allograft and xenograft tissue into shaped implants for use in orthopedic, cardiovascular and other surgeries with a commitment to science, safety and innovation.
RTI also holds the patents on BioCleanse, the only proven tissue sterilization process validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the tissue. The company has distributed more than half a million Allograft implants sterilized with the BioCleanse process with zero incidence of infection. RTI is accredited by the American Association of Tissue Banks and was named a 2004 Technology Pioneer by the World Economic Forum.
Except for historical information, any statements made in this press release about the company's anticipated financial results, future operational results, regulatory approvals or changes to the company's agreements with its distributors are forward-looking statements subject to risks and uncertainties, such as those described in the company's public filings on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's web site at www.rtix.com or the SEC's web site at www.sec.gov.
Source: Regeneration Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.